A Phase 2 interventional study of OG-6219 and Placebo in Endometriosis, sponsored by Organon and Co. Completed at 86 sites in 11 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Organon and Co · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 169 studies in Endometriosis with a site in United States — 38 open to participants now, 48 under way, 5 of them phase 3. Endometriosis · United States.
Among the 169 studies in Endometriosis with a site in United States, this one is the 12th largest by enrollment of the 131 interventional ones that give a count, is one of 15 that started in 2022, is one of 39 in phase 2, and was the 123rd registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →38 of the 169 studies in Endometriosis with a site in United States are open now. Recruiting first, the newest first:
SWIMS America Corp. · Sites in United States
Ages 18+ · Women only
LOAM Science · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Milton S. Hershey Medical Center · Sites in United States
Ages 18–45
Christiana Care Health Services · Sites in United States
Ages 18+ · Women only
Staci Gruber, Ph.D. · Sites in United States
Ages 21+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
169 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 45 · Phase 3 22 · Phase 4 14
First in 1998; this study’s year is marked. 15 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 354 is above the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 60 across the 131 interventional studies, 187 across the 38 observational. Of the 102 that completed or were terminated, 50 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 169 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Organon & Co. has 3 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
23 of the studies in Endometriosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT04333576Phase 3AbbVieStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | 2027-07 |
| NCT05245695Aspira Women's HealthDeep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) | 2026-11-30 |
| NCT06477406Mclean HospitalEvaluating the Impact of a Novel Cannabinoid Product for Endometriosis | 2026-12 |
| NCT05059626Penn State UniversityEndometriosis and Microvascular Dysfunction; Simvastatin and Duavee | 2026-12-31 |
Add all 23 to your calendar (.ics) → With an account.
Among the 169 studies in Endometriosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
This is a global multicenter, Phase 2a/b, randomized, double-blind, Placebo-controlled study to assess the efficacy, safety, and tolerability of 3 dose levels of OG-6219, in pre-menopausal women 18 to 49 years of age (inclusive), who have been surgically diagnosed with endometriosis with moderate to severe endometriosis-related pain. This study includes treatment lasting approximately 16 weeks in total and is followed by a Safety Follow-up visit.
Pre-menopausal females aged 18 to 49 years old (inclusive), who have been surgically diagnosed with endometriosis will be screened and randomly assigned to study treatment. A minimum subset of 10 participants per treatment group (including Placebo group) will be voluntarily enrolled for optional intensive PK sampling for the entire duration of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A: OG-6219 Dose 1 BID
Drug: OG-6219
Group B: OG-6219 Dose 2 BID
Drug: OG-6219
Group C: OG-6219 Dose 3 BID
Drug: OG-6219
Group D: Placebo BID
Drug: Placebo
OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3
Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea or NMPP, and dyspareunia. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean OPP score was derived by the pain score for the dysmenorrhea and NMPP items, and score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. Baseline cycle OPP score was defined as the average daily OPP during baseline cycle.
Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. TEAEs were defined as events that first occur or worsen (increase in severity) after the first dose of study drug, during the treatment period, and up to 14 days (inclusive) after the last dose of study drug administration. Percentages are rounded off to the hundredth decimal place.
Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation
An AE was defined as any untoward medical occurrence in a clinical study participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that first occur or worsen (increase in severity) after the first dose of study drug, during the treatment period, and up to 14 days (inclusive) after the last dose of study drug administration. The TEAEs leading to permanent discontinuation of study drug was identified by using the 'Action taken with study treatment' variable equal to 'Drug withdrawal' from the AE page of the electronic case report form. Percentages are rounded off to the hundredth decimal place.
Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
Change From Baseline Cycle in Mean Dysmenorrhea Score at Treatment Cycle 3
Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean dysmenorrhea score was calculated for each cycle as the total of daily dysmenorrhea scores reported during the cycle divided by the number of days during the cycle when a dysmenorrhea score was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Change From Baseline Cycle in Mean Non-Menstrual Pelvic Pain Score at Treatment Cycle 3
Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean NMPP score was calculated for each cycle as the total of daily NMPP scores reported during the cycle divided by the number of days during the cycle when a NMPP score was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Change From Baseline Cycle in Mean Dyspareunia Score at Treatment Cycle 3
Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dyspareunia. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean dyspareunia score was calculated for each cycle as the total of dyspareunia scores reported during each cycle divided by the number of days when participants engaged in any sexual activity that involved full vaginal penetration during each cycle (that is, the number of days during the baseline cycle when a dyspareunia score was reported). Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Change From Baseline Cycle in Mean Number of Rescue Medication Tablets Used for Endometriosis-Related Pain at Treatment Cycles 1, 2 and 3
Participants were asked daily whether they used the rescue medication in the past 24 hours to treat their ERP. If yes, the number of tablets was documented. The mean number of tablets of rescue medication for ERP was calculated for each cycle as the total number of tablets of rescue medication for ERP reported during the cycle, divided by the number of days during the cycle when a value was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
Time frame: Baseline Cycle (up to Day -28) and Treatment Cycles 1 (Day 32), 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Change From Baseline Cycle in Percentage of Days With Participants Used Rescue Medication for Endometriosis-Related Pain at Treatment Cycles 1, 2 and 3
Participants were asked daily whether they used the rescue medication in the past 24 hours to treat their ERP. If yes, the number of tablets was documented. The percentage of days participant had used rescue medication for ERP was calculated for each cycle as the total number of days participant had used any rescue medication for ERP, divided by the number of days during the cycle when a value was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
Time frame: Baseline Cycle (up to Day -28) and Treatment Cycles 1 (Day 32), 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Change From Start of Treatment Cycle 1 in Participants With Patient Global Impression of Severity (PGI-S) to Start of Treatment Cycle 2, End of Treatment Cycles 2 and 3
The PGI-S was a single item measuring the overall severity of pelvic pain over the past 7 days on a 4-point Likert-type scale (0=None, 1=Mild, 2=Moderate, 3=Severe), score ranged from 0 (none) and 3 (severe), where lower score indicated a better outcome. Treatment Cycle 1 was the period between the first day of menses associated with treatment start (Visit 4) to the day prior to the first day of next menses, regardless of number of days.
Time frame: Start of Treatment Cycle 1 (Day 1) and start of Treatment Cycle 2 (Day 33), end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Percentage of Participants With Any Improvement on the Patient Global Impression of Change (PGI-C) at Start of Treatment Cycle 2 and End of Treatment Cycles 2 and 3
The PGI-C was a single item measuring the change in pelvic pain since the start of the study drug on a 5-point scale (0=much better, 1=a little better, 2=no change, 3=a little worse, 4=much worse), score ranged from 0 (much better) and 4 (much worse), where lower score indicated a better outcome. Participants with any improvement on the PGI-C were defined as a PGI-C score of 0 or 1 (0=much better and 1=a little better). Treatment Cycle 2 was the period between the first day of menses associated with start of treatment Cycle 2 to the day prior to the first day of next menses, regardless of number of days.
Time frame: Start of Treatment Cycle 2 (Day 33), end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Change From Baseline Cycle in Endometriosis Health Profile-30 (EHP-30) Domains Score at Treatment Cycle 3
The EHP-30 was a validated disease specific patient-reported outcome instrument measuring the health-related quality of life of women with endometriosis on a 5-point Likert-type scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=always). The EHP-30 consisted of 30 items with following domains: pain (11 items), score ranged from 0 (never) to 44 (always); controls and powerlessness (6 items), score ranged from 0 (never) to 24 (always); emotional well-being (6 items), score ranged from 0 (never) to 24 (always); social support (4 items), score ranged from 0 (never) to 16 (always); and self-image (3 items), score ranged from 0 (never) to 12 (always). Each domain lower score indicated a better outcome. Total EHP-30 score ranged from 0 (never) and 120 (always), where lower score indicated a better outcome. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Mean Change From Screening in C-Telopeptide of Type I Collagen (CTX) and Procollagen Type I N-Terminal Propeptide (P1NP) at End of Treatment Cycle 3
Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing CTX level and bone formation was determined by assessing P1NP level. Screening (Visit 1) was defined as the last measurement before study drug administration.
Time frame: Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Mean Change From Screening in Bone-Specific Alkaline Phosphatase (BSAP) and Osteocalcin at End of Treatment Cycle 3
Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone formation was determined by assessing BSAP and osteocalcin level. Screening (Visit 1) was defined as the last measurement before study drug administration.
Time frame: Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Mean Change From Screening in N-Telopeptide of Type I Collagen (NTX) at End of Treatment Cycle 3
Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing NTX level. Screening (Visit 1) was defined as the last measurement before study drug administration. nmol BCE/L= nanomoles of bone collagen equivalents per liter.
Time frame: Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Mean Change From Screening in Tartrate-Resistant Acid Phosphatase 5b (TRAP5b) at End of Treatment Cycle 3
Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing TRAP5b level. Screening (Visit 1) was defined as the last measurement before study drug administration.
Time frame: Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Number of Participants With Clinically Significant Laboratory Abnormalities
Blood samples were collected to determine the clinical laboratory abnormalities. The laboratory assessments included chemistry, hematology and urinalysis.
Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
Mean Change From Baseline Cycle in Sum of Days on Period at Treatment Cycles 1, 2 and 3
Participants recorded the presence of bleeding or spotting daily in the eDiary. The daily questions to assess bleeding pattern in the eDiary were "1a: During the past 24 hours, did you have any vaginal bleeding or spotting? If the response is "Yes", then the next question is, "1b: During the past 24 hours, have you been on your period?". Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
Time frame: Baseline Cycle (up to Day -28) and Treatment Cycles 1 (Day 32), 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Number of Participants With Clinically Significant Electrocardiogram (ECG) Parameters Abnormalities
Triplicate standard 12-lead ECGs was obtained after the participant was in supine position for at least 5 minutes. The ECG measurements was summarized by taking the average of the available assessments. Only clinically significant ECG abnormalities are reported.
Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
Mean Change From Screening in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
Blood samples were collected to determine the serum level of LH and FSH. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Mean Change From Screening in Estrone (E1) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
Blood samples were collected to determine the serum level of E1. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Mean Change From Screening in Progesterone, Testosterone and Dehydroepiandrosterone (DHEA) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
Blood samples were collected to determine the serum level of progesterone, testosterone and DHEA. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Mean Change From Screening in Free Testosterone and Estradiol (E2) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
Blood samples were collected to determine the serum level of free testosterone and E2. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Mean Change From Screening in Dehydroepiandrosterone Sulfate (DHEAS) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
Blood samples were collected to determine the serum level of DHEAS. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Plasma Concentrations of OG-6219 and FOR-1011
Blood samples were collected to determine plasma concentration of OG-6219 and FOR-1011. The plasma concentration of OG-6219 and FOR-1011 was analyzed using an appropriate validated bioanalytical method.
Time frame: Pre-witness dose and 1.5 hours postdose on start of Treatment Cycle 1 (Day 1), at 7 days after urine LH surge, and end of Treatment Cycle 2; Pre-witness dose on end of Treatment Cycle 3
Maximum Concentration (Cmax) of OG-6219 and FOR-1011
Blood samples were collected to determine Cmax of OG-6219 and FOR-1011. The Cmax of OG-6219 and FOR-1011 was calculated using non-compartmental method. NCA= Noncompartmental analysis.
Time frame: Pre-witness dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose on start of Treatment Cycle 1 (Day 1) and at 7 days after urine LH surge
Time Taken to Reach the Maximum Concentration (Tmax) of OG-6219 and FOR-1011
Blood samples were collected to determine tmax of OG-6219 and FOR-1011. The tmax of OG-6219 and FOR-1011 was calculated using non-compartmental method.
Time frame: Pre-witness dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose on start of Treatment Cycle 1 (Day 1) and at 7 days after urine LH surge
Area Under the Plasma Concentration-Time Curve During a Dosing Interval (AUCtau) of OG-6219 and FOR-1011
Blood samples were collected to determine AUCtau of OG-6219 and FOR-1011. The AUCtau of OG-6219 and FOR-1011 was calculated using non-compartmental method.
Time frame: Pre-witness dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose on start of Treatment Cycle 1 (Day 1) and at 7 days after urine LH surge
This Phase 2a/b, double-blind, placebo-controlled study was conducted in pre-menopausal women 18 to 49 years of age with moderate to severe endometriosis-related pain (ERP) at 93 centers in 11 countries between 25 October 2022 and 28 May 2025.
| Milestone | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Started | 88 | 89 | 88 | 89 |
| Completed | 78 | 78 | 81 | 78 |
| Not completed | 10 | 11 | 7 | 11 |
| Withdrew: Adverse event | 3 | 2 | 0 | 4 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 4 | 1 | 1 |
| Withdrew: Other | 3 | 2 | 2 | 0 |
Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea or NMPP, and dyspareunia. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean OPP score was derived by the pain score for the dysmenorrhea and NMPP items, and score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. Baseline cycle OPP score was defined as the average daily OPP during baseline cycle.
| score on a scale | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3 | -1.8 ± 1.94 | -1.6 ± 1.86 | -1.5 ± 1.80 | -2.0 ± 2.12 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. TEAEs were defined as events that first occur or worsen (increase in severity) after the first dose of study drug, during the treatment period, and up to 14 days (inclusive) after the last dose of study drug administration. Percentages are rounded off to the hundredth decimal place.
| percentage of participants | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Any TEAE | 51.1 | 52.3 | 51.1 | 55.1 |
| Any TESAE | 0 | 1.1 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a clinical study participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that first occur or worsen (increase in severity) after the first dose of study drug, during the treatment period, and up to 14 days (inclusive) after the last dose of study drug administration. The TEAEs leading to permanent discontinuation of study drug was identified by using the 'Action taken with study treatment' variable equal to 'Drug withdrawal' from the AE page of the electronic case report form. Percentages are rounded off to the hundredth decimal place.
| percentage of participants | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation | 3.4 | 2.3 | 1.1 | 5.6 |
Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean dysmenorrhea score was calculated for each cycle as the total of daily dysmenorrhea scores reported during the cycle divided by the number of days during the cycle when a dysmenorrhea score was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
| score on a scale | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Change From Baseline Cycle in Mean Dysmenorrhea Score at Treatment Cycle 3 | -1.9 ± 2.23 | -1.5 ± 1.94 | -1.5 ± 2.16 | -1.9 ± 2.29 |
Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean NMPP score was calculated for each cycle as the total of daily NMPP scores reported during the cycle divided by the number of days during the cycle when a NMPP score was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
| score on a scale | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Change From Baseline Cycle in Mean Non-Menstrual Pelvic Pain Score at Treatment Cycle 3 | -1.9 ± 2.03 | -1.6 ± 2.03 | -1.5 ± 1.86 | -2.1 ± 2.24 |
Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dyspareunia. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean dyspareunia score was calculated for each cycle as the total of dyspareunia scores reported during each cycle divided by the number of days when participants engaged in any sexual activity that involved full vaginal penetration during each cycle (that is, the number of days during the baseline cycle when a dyspareunia score was reported). Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
| score on a scale | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Change From Baseline Cycle in Mean Dyspareunia Score at Treatment Cycle 3 | -1.5 ± 2.32 | -1.3 ± 2.11 | -1.5 ± 2.21 | -1.2 ± 2.61 |
Participants were asked daily whether they used the rescue medication in the past 24 hours to treat their ERP. If yes, the number of tablets was documented. The mean number of tablets of rescue medication for ERP was calculated for each cycle as the total number of tablets of rescue medication for ERP reported during the cycle, divided by the number of days during the cycle when a value was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
| mean number of tablets | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Treatment Cycle 1 | -0.2 ± 0.38 | -0.2 ± 0.44 | -0.2 ± 0.46 | -0.2 ± 0.42 |
| Treatment Cycle 2 | -0.2 ± 0.55 | -0.2 ± 0.43 | -0.2 ± 0.39 | -0.2 ± 0.50 |
| Treatment Cycle 3 | -0.3 ± 0.54 | -0.3 ± 0.47 | -0.3 ± 0.55 | -0.2 ± 0.58 |
Participants were asked daily whether they used the rescue medication in the past 24 hours to treat their ERP. If yes, the number of tablets was documented. The percentage of days participant had used rescue medication for ERP was calculated for each cycle as the total number of days participant had used any rescue medication for ERP, divided by the number of days during the cycle when a value was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
| percentage of days | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Treatment Cycle 1 | -10.7 ± 21.42 | -8.7 ± 18.40 | -9.2 ± 19.23 | -14.1 ± 21.12 |
| Treatment Cycle 2 | -15.6 ± 27.95 | -9.8 ± 16.97 | -10.2 ± 19.42 | -15.9 ± 25.11 |
| Treatment Cycle 3 | -18.7 ± 28.52 | -13.2 ± 19.04 | -14.2 ± 24.17 | -16.4 ± 29.04 |
The PGI-S was a single item measuring the overall severity of pelvic pain over the past 7 days on a 4-point Likert-type scale (0=None, 1=Mild, 2=Moderate, 3=Severe), score ranged from 0 (none) and 3 (severe), where lower score indicated a better outcome. Treatment Cycle 1 was the period between the first day of menses associated with treatment start (Visit 4) to the day prior to the first day of next menses, regardless of number of days.
| Participants | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Start of Treatment Cycle 2 — None | 4 | 3 | 6 | 7 |
| Start of Treatment Cycle 2 — Mild | 23 | 17 | 12 | 17 |
| Start of Treatment Cycle 2 — Moderate | 35 | 38 | 39 | 39 |
| Start of Treatment Cycle 2 — Severe | 23 | 23 | 25 | 21 |
| End of Treatment Cycle 2 — None | 3 | 2 | 9 | 6 |
| End of Treatment Cycle 2 — Mild | 24 | 21 | 18 | 21 |
| End of Treatment Cycle 2 — Moderate | 36 | 35 | 31 | 32 |
| End of Treatment Cycle 2 — Severe | 17 | 21 | 24 | 21 |
| End of Treatment Cycle 3 — None | 6 | 7 | 12 | 17 |
| End of Treatment Cycle 3 — Mild | 27 | 24 | 17 | 26 |
| End of Treatment Cycle 3 — Moderate | 29 | 29 | 36 | 20 |
| End of Treatment Cycle 3 — Severe | 17 | 17 | 15 | 15 |
The PGI-C was a single item measuring the change in pelvic pain since the start of the study drug on a 5-point scale (0=much better, 1=a little better, 2=no change, 3=a little worse, 4=much worse), score ranged from 0 (much better) and 4 (much worse), where lower score indicated a better outcome. Participants with any improvement on the PGI-C were defined as a PGI-C score of 0 or 1 (0=much better and 1=a little better). Treatment Cycle 2 was the period between the first day of menses associated with start of treatment Cycle 2 to the day prior to the first day of next menses, regardless of number of days.
| percentage of participants | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Start of Treatment Cycle 2 | 56.8 | 60.2 | 51.1 | 61.8 |
| End of Treatment Cycle 2 | 62.5 | 64.8 | 62.5 | 66.3 |
| End of Treatment Cycle 3 | 65.9 | 60.2 | 64.8 | 66.3 |
The EHP-30 was a validated disease specific patient-reported outcome instrument measuring the health-related quality of life of women with endometriosis on a 5-point Likert-type scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=always). The EHP-30 consisted of 30 items with following domains: pain (11 items), score ranged from 0 (never) to 44 (always); controls and powerlessness (6 items), score ranged from 0 (never) to 24 (always); emotional well-being (6 items), score ranged from 0 (never) to 24 (always); social support (4 items), score ranged from 0 (never) to 16 (always); and self-image (3 items), score ranged from 0 (never) to 12 (always). Each domain lower score indicated a better outcome. Total EHP-30 score ranged from 0 (never) and 120 (always), where lower score indicated a better outcome. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
| score on a scale | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Pain Scale Score | -21.04 ± 18.714 | -20.96 ± 19.753 | -19.75 ± 19.016 | -24.62 ± 24.276 |
| Controls and Powerlessness Scale Score | -23.93 ± 26.747 | -22.75 ± 23.780 | -18.61 ± 27.319 | -28.58 ± 30.104 |
| Emotional Well-Being Scale Score | -17.41 ± 18.667 | -16.78 ± 21.322 | -12.07 ± 20.103 | -17.09 ± 23.229 |
| Social Support Scale Score | -18.43 ± 23.470 | -17.11 ± 23.170 | -9.01 ± 25.719 | -19.71 ± 29.073 |
| Self-Image Scale Score | -15.60 ± 23.736 | -14.91 ± 22.498 | -14.61 ± 23.027 | -14.74 ± 27.324 |
Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing CTX level and bone formation was determined by assessing P1NP level. Screening (Visit 1) was defined as the last measurement before study drug administration.
| nanogram per milliliter (ng/mL) | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| CTX | 0.0 ± 0.12 | 0.0 ± 0.14 | 0.0 ± 0.16 | 0.0 ± 0.16 |
| P1NP | 2.3 ± 15.68 | -1.7 ± 12.66 | -0.2 ± 17.90 | -3.6 ± 14.39 |
Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone formation was determined by assessing BSAP and osteocalcin level. Screening (Visit 1) was defined as the last measurement before study drug administration.
| microgram per liter | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| BSAP | 0.3 ± 2.00 | -0.7 ± 2.00 | -0.1 ± 2.52 | -0.5 ± 1.83 |
| Osteocalcin | 0.8 ± 4.72 | -0.8 ± 3.69 | -0.6 ± 5.28 | -1.5 ± 4.08 |
Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing NTX level. Screening (Visit 1) was defined as the last measurement before study drug administration. nmol BCE/L= nanomoles of bone collagen equivalents per liter.
| nmol BCE/L | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Mean Change From Screening in N-Telopeptide of Type I Collagen (NTX) at End of Treatment Cycle 3 | 29.8 ± 421.15 | 28.2 ± 268.19 | 1.7 ± 398.93 | 9.0 ± 386.61 |
Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing TRAP5b level. Screening (Visit 1) was defined as the last measurement before study drug administration.
| units per liter | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Mean Change From Screening in Tartrate-Resistant Acid Phosphatase 5b (TRAP5b) at End of Treatment Cycle 3 | -0.1 ± 0.56 | -0.4 ± 1.04 | -0.3 ± 0.56 | -0.4 ± 0.96 |
Blood samples were collected to determine the clinical laboratory abnormalities. The laboratory assessments included chemistry, hematology and urinalysis.
| Participants | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Activated partial thromboplastin time prolonged | 0 | 0 | 1 | 0 |
| Alanine aminotransferase increased | 0 | 0 | 1 | 0 |
| Aspartate aminotransferase increased | 0 | 0 | 1 | 0 |
| Gamma-glutamyltransferase increased | 1 | 1 | 1 | 0 |
| Blood triglycerides increased | 0 | 0 | 1 | 0 |
| Blood testosterone free increased | 0 | 0 | 0 | 1 |
| Blood testosterone increased | 0 | 0 | 0 | 1 |
| Hepatic enzyme increased | 0 | 0 | 0 | 1 |
| Hyperlipidaemia | 0 | 0 | 0 | 1 |
| Methaemoglobinaemia | 0 | 0 | 1 | 3 |
Participants recorded the presence of bleeding or spotting daily in the eDiary. The daily questions to assess bleeding pattern in the eDiary were "1a: During the past 24 hours, did you have any vaginal bleeding or spotting? If the response is "Yes", then the next question is, "1b: During the past 24 hours, have you been on your period?". Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.
| days | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Treatment Cycle 1 | -0.1 ± 1.47 | -0.3 ± 1.87 | -0.2 ± 1.85 | 0.2 ± 2.50 |
| Treatment Cycle 2 | -0.3 ± 1.64 | -0.2 ± 2.33 | -0.3 ± 1.55 | -0.5 ± 2.59 |
| Treatment Cycle 3 | -0.3 ± 1.82 | -0.7 ± 1.93 | -0.8 ± 2.32 | -0.6 ± 2.32 |
Triplicate standard 12-lead ECGs was obtained after the participant was in supine position for at least 5 minutes. The ECG measurements was summarized by taking the average of the available assessments. Only clinically significant ECG abnormalities are reported.
| Participants | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Electrocardiogram QT prolonged | 2 | 1 | 0 | 2 |
| Electrocardiogram T wave abnormal | 1 | 0 | 0 | 0 |
Blood samples were collected to determine the serum level of LH and FSH. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
| international units per liter | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| LH: 7 days after urine LH surge | -0.0 ± 9.23 | -0.6 ± 8.33 | -1.5 ± 7.05 | 2.3 ± 19.52 |
| LH: end of Treatment Cycle 2 | -0.1 ± 8.17 | -0.6 ± 4.51 | 1.4 ± 9.49 | -0.1 ± 5.55 |
| LH: end of Treatment Cycle 3 | 1.4 ± 13.17 | 2.0 ± 9.63 | 0.4 ± 8.92 | 1.6 ± 7.27 |
| FSH: 7 days after urine LH surge | -0.1 ± 15.04 | -3.2 ± 5.63 | -3.9 ± 6.75 | -3.8 ± 10.80 |
| FSH: end of Treatment Cycle 2 | 0.6 ± 12.21 | -0.4 ± 5.97 | 1.2 ± 10.87 | -0.5 ± 17.71 |
| FSH: end of Treatment Cycle 3 | 2.5 ± 18.86 | 1.3 ± 9.64 | -1.2 ± 8.10 | 1.2 ± 18.47 |
Blood samples were collected to determine the serum level of E1. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
| picogram per mL | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| 7 days after urine LH surge | -7.8 ± 141.76 | 41.5 ± 185.63 | 25.6 ± 63.91 | 51.9 ± 209.01 |
| End of Treatment Cycle 2 | -28.1 ± 136.75 | 50.5 ± 379.65 | -7.0 ± 62.03 | -17.1 ± 111.62 |
| End of Treatment Cycle 3 | -25.5 ± 144.27 | 47.1 ± 354.49 | -3.9 ± 46.75 | -3.8 ± 136.91 |
Blood samples were collected to determine the serum level of progesterone, testosterone and DHEA. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
| nanomoles per liter | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Progesterone: 7 days after urine LH surge | 11.5 ± 19.49 | 14.8 ± 20.82 | 17.7 ± 21.23 | 11.9 ± 26.11 |
| Progesterone: End of Treatment Cycle 2 | -0.8 ± 8.51 | 0.2 ± 9.48 | 0.2 ± 10.66 | -2.2 ± 14.58 |
| Progesterone: End of Treatment Cycle 3 | -0.4 ± 10.33 | 1.1 ± 8.24 | 2.1 ± 16.14 | -1.9 ± 14.19 |
| Testosterone: 7 days after urine LH surge | -0.0 ± 0.34 | 0.0 ± 0.36 | 0.0 ± 0.33 | 0.1 ± 1.07 |
| Testosterone: End of Treatment Cycle 2 | 0.0 ± 0.37 | -0.0 ± 0.37 | -0.0 ± 0.33 | -0.0 ± 0.28 |
| Testosterone: End of Treatment Cycle 3 | -0.0 ± 0.33 | 0.1 ± 0.45 | 0.0 ± 0.28 | -0.0 ± 0.27 |
| DHEA: 7 days after urine LH surge | -1.2 ± 6.80 | -0.2 ± 7.29 | -1.6 ± 8.89 | 1.3 ± 7.50 |
| DHEA: End of Treatment Cycle 2 | 0.5 ± 9.86 | -0.0 ± 6.65 | -1.3 ± 8.34 | 2.2 ± 8.36 |
| DHEA: End of Treatment Cycle 3 | -0.0 ± 7.12 | 0.4 ± 6.65 | -0.5 ± 8.07 | 2.5 ± 13.25 |
Blood samples were collected to determine the serum level of free testosterone and E2. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
| picomoles per liter | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Free Testosterone: 7 days after urine LH surge | 0.1 ± 4.85 | 0.8 ± 5.36 | 0.4 ± 4.30 | 1.8 ± 9.93 |
| Free Testosterone: End of Treatment Cycle 2 | 0.1 ± 4.94 | 0.4 ± 5.50 | 0.7 ± 3.92 | 0.4 ± 3.17 |
| Free Testosterone: End of Treatment Cycle 3 | 0.1 ± 4.50 | 0.6 ± 4.62 | 0.9 ± 3.59 | 0.6 ± 3.51 |
| E2: 7 days after urine LH surge | -10.6 ± 693.72 | 74.4 ± 424.18 | 134.1 ± 385.35 | 180.3 ± 301.65 |
| E2: End of Treatment Cycle 2 | -76.5 ± 676.83 | -11.9 ± 423.16 | 7.8 ± 384.11 | 65.6 ± 370.86 |
| E2: End of Treatment Cycle 3 | -104.0 ± 734.49 | 21.8 ± 432.57 | 59.7 ± 368.94 | 52.3 ± 317.51 |
Blood samples were collected to determine the serum level of DHEAS. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.
| micromoles per liter | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| 7 days after urine LH surge | 0.2 ± 1.73 | 0.1 ± 1.48 | 0.5 ± 1.83 | 0.5 ± 1.61 |
| End of Treatment Cycle 2 | 0.2 ± 1.59 | -0.0 ± 1.26 | 0.4 ± 1.88 | 0.4 ± 1.59 |
| End of Treatment Cycle 3 | 0.3 ± 1.63 | -0.0 ± 1.46 | 0.4 ± 1.50 | 0.4 ± 1.76 |
Blood samples were collected to determine plasma concentration of OG-6219 and FOR-1011. The plasma concentration of OG-6219 and FOR-1011 was analyzed using an appropriate validated bioanalytical method.
| ng/mL | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|
| OG-6219: start of Treatment Cycle 1: Pre-witness dose | 0.977 ± 8.6860 | 8.035 ± 56.5220 | 5.360 ± 49.7109 |
| OG-6219: start of Treatment Cycle 1: 1.5 hours postdose | 190.754 ± 111.7670 | 356.706 ± 214.6828 | 610.430 ± 347.2826 |
| OG-6219: 7 days after urine LH surge: Pre-witness dose | 41.467 ± 42.1563 | 154.748 ± 181.5646 | 159.431 ± 177.0591 |
| OG-6219: 7 days after urine LH surge: 1.5 hours postdose | 220.459 ± 115.9525 | 456.157 ± 231.4797 | 727.633 ± 378.6709 |
| OG-6219: end of Treatment Cycle 2: Pre-witness dose | 45.379 ± 50.9615 | 96.369 ± 97.4646 | 144.031 ± 125.8066 |
| OG-6219: end of Treatment Cycle 2: 1.5 hours postdose | 220.166 ± 130.5234 | 454.316 ± 273.4854 | 698.483 ± 424.0240 |
| OG-6219: end of Treatment Cycle 3: Pre-witness dose | 46.249 ± 45.4428 | 102.244 ± 121.2036 | 134.696 ± 129.7118 |
| FOR-1011: start of Treatment Cycle 1: Pre-witness dose | 1.140 ± 10.4526 | 6.314 ± 48.3585 | 2.488 ± 23.0762 |
| FOR-1011: start of Treatment Cycle 1: 1.5 hours postdose | 113.709 ± 120.1908 | 227.374 ± 168.6837 | 367.034 ± 289.7623 |
| FOR-1011: 7 days after urine LH surge: Pre-witness dose | 95.390 ± 73.7511 | 322.026 ± 235.8709 | 429.356 ± 263.5069 |
| FOR-1011: 7 days after urine LH surge: 1.5 hours postdose | 219.654 ± 133.2333 | 579.185 ± 309.3082 | 933.811 ± 540.2559 |
| FOR-1011: end of Treatment Cycle 2: Pre-witness dose | 94.372 ± 69.6035 | 245.359 ± 175.9825 | 415.913 ± 254.7596 |
| FOR-1011: end of Treatment Cycle 2: 1.5 hours postdose | 212.727 ± 129.1773 | 503.827 ± 312.9332 | 777.500 ± 426.8007 |
| FOR-1011: end of Treatment Cycle 3: Pre-witness dose | 90.638 ± 75.9499 | 246.690 ± 191.3304 | 367.871 ± 279.6791 |
Blood samples were collected to determine Cmax of OG-6219 and FOR-1011. The Cmax of OG-6219 and FOR-1011 was calculated using non-compartmental method. NCA= Noncompartmental analysis.
| ng/mL | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|
| OG-6219: start of Treatment Cycle 1 | 328.000 ± 187.7640 | 344.500 ± 19.0919 | — |
| OG-6219: 7 days after urine LH surge | 227.000 ± 37.7536 | 560.000 ± 76.3675 | — |
| FOR-1011: start of Treatment Cycle 1 | 142.000 ± 48.4493 | 149.000 ± 26.8701 | — |
| FOR-1011: 7 days after urine LH surge | 179.250 ± 63.5997 | 801.500 ± 276.4788 | — |
Blood samples were collected to determine tmax of OG-6219 and FOR-1011. The tmax of OG-6219 and FOR-1011 was calculated using non-compartmental method.
| hour | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|
| OG-6219: start of Treatment Cycle 1 | 2.0000 (2.000 to 2.500) | 2.4900 (0.980 to 4.000) | — |
| OG-6219: 7 days after urine LH surge | 1.2500 (0.980 to 2.000) | 2.0100 (1.500 to 2.520) | — |
| FOR-1011: start of Treatment Cycle 1 | 2.5000 (2.500 to 2.970) | 3.5100 (3.020 to 4.000) | — |
| FOR-1011: 7 days after urine LH surge | 2.0000 (1.530 to 2.500) | 2.7600 (2.520 to 3.000) | — |
Blood samples were collected to determine AUCtau of OG-6219 and FOR-1011. The AUCtau of OG-6219 and FOR-1011 was calculated using non-compartmental method.
| hour*ng/mL | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|
| OG-6219: start of Treatment Cycle 1 | 1049.827 ± 480.0726 | 1838.584 ± 339.6732 | — |
| OG-6219: 7 days after urine LH surge | 1259.562 ± 459.8191 | 3554.051 ± 97.8206 | — |
| FOR-1011: start of Treatment Cycle 1 | 679.947 ± 110.4275 | 993.293 ± 120.8272 | — |
| FOR-1011: 7 days after urine LH surge | 1342.994 ± 566.4143 | 5807.653 ± 1512.6682 | — |
Collected over TEAEs are reported from the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/88 (0%) | 0/88 (0%) | 45/88 (51.1%) |
| OG-6219 50 mg | 0/88 (0%) | 1/88 (1.1%) | 46/88 (52.3%) |
| OG-6219 100 mg | 0/88 (0%) | 0/88 (0%) | 45/88 (51.1%) |
| OG-6219 150 mg | 0/89 (0%) | 0/89 (0%) | 49/89 (55.1%) |
| Event | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/88 | 1/88 | 0/88 | 0/89 |
| Event | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg |
|---|---|---|---|---|
| HeadacheNervous system disorders | 13/88 | 15/88 | 22/88 | 18/89 |
| Upper respiratory tract infectionInfections and infestations | 10/88 | 10/88 | 4/88 | 7/89 |
| NasopharyngitisInfections and infestations | 6/88 | 1/88 | 2/88 | 3/89 |
| RhinitisInfections and infestations | 1/88 | 0/88 | 5/88 | 1/89 |
| NauseaGastrointestinal disorders | 4/88 | 2/88 | 3/88 | 0/89 |
| Urinary tract infectionInfections and infestations | 1/88 | 4/88 | 2/88 | 1/89 |
| InfluenzaInfections and infestations | 1/88 | 4/88 | 1/88 | 1/89 |
| DiarrhoeaGastrointestinal disorders | 2/88 | 3/88 | 1/88 | 3/89 |
| DizzinessNervous system disorders | 3/88 | 0/88 | 2/88 | 2/89 |
| EndometriosisReproductive system and breast disorders | 1/88 | 3/88 | 2/88 | 2/89 |
Full analysis set included all randomized participants.
| Age, Categorical(Participants) | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 88 | 89 | 88 | 89 | 354 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg | Total |
|---|---|---|---|---|---|
| Female | 88 | 89 | 88 | 89 | 354 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg | Total |
|---|---|---|---|---|---|
| Black or African American | 2 | 0 | 1 | 1 | 4 |
| White | 83 | 86 | 86 | 87 | 342 |
| Multiple | 1 | 0 | 1 | 0 | 2 |
| Unknown | 1 | 2 | 0 | 0 | 3 |
| Not Reported | 1 | 1 | 0 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 7 | 0 | 1 | 13 |
| Not Hispanic or Latino | 82 | 81 | 88 | 86 | 337 |
| Unknown | 0 | 0 | 0 | 1 | 1 |
| Not Reported | 1 | 1 | 0 | 1 | 3 |
| Region of Enrollment(Participants) | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg | Total |
|---|---|---|---|---|---|
| Belgium | 4 | 2 | 3 | 0 | 9 |
| Bulgaria | 6 | 2 | 5 | 2 | 15 |
| Czechia | 5 | 3 | 4 | 6 | 18 |
| France | 1 | 1 | 0 | 1 | 3 |
| Germany | 2 | 1 | 0 | 0 | 3 |
| Hungary | 3 | 4 | 1 | 2 | 10 |
| Italy | 0 | 1 | 0 | 1 | 2 |
| Latvia | 1 | 3 | 2 | 4 | 10 |
| Poland | 58 | 65 | 63 | 66 | 252 |
| Sweden | 2 | 1 | 2 | 0 | 5 |
| United States | 6 | 6 | 8 | 7 | 27 |
| Overall Pelvic Pain (OPP) Score(score on a scale) | Placebo | OG-6219 50 mg | OG-6219 100 mg | OG-6219 150 mg | Total |
|---|---|---|---|---|---|
| Mean | 5.6 ± 1.51 | 6.0 ± 1.56 | 5.7 ± 1.67 | 5.8 ± 1.69 | 5.8 ± 1.61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in May 2025, 31 months.
Results were first posted in May 2026, 11 months after primary completion.
Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 31 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linustedastat